Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Inv. presentation
Auditor change
|
|
Cellular Biomedicine Group, Inc. (CBMG)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/03/2021 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 02/26/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/26/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/26/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/19/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 02/19/2021 |
SC 13D/A
| Liu Tony reports a 0% stake in Cellular Biomedicine Group, Inc. |
| 02/19/2021 |
4
| Au Chun Kwok Alan (Director) has filed a Form 4 on Cellular Biomedicine Group, Inc.|
Txns:
| Disposed/sold 4,000 options to buy
@ $15.62, valued at
$62.5k
Disposed/sold 5,056 options to buy
@ $20, valued at
$101.1k
Disposed/sold 2,060 options to buy
@ $20, valued at
$41.2k
Disposed/sold 9,789 options to buy
@ $13.35, valued at
$130.7k
Disposed/sold 12,056 options to buy
@ $10.8, valued at
$130.2k
Disposed/sold 7,213 options to buy
@ $19.71, valued at
$142.2k
Disposed/sold 2,238 options to buy
@ $17, valued at
$38k
Disposed/sold 1,390 options to buy
@ $17.89, valued at
$24.9k
Disposed/sold 6,348 options to buy
@ $0 |
|
| 02/19/2021 |
4
| Ji Gang Jacky (Director) has filed a Form 4 on Cellular Biomedicine Group, Inc.|
Txns:
| Disposed/sold 3,620 options to buy
@ $14.7, valued at
$53.2k
Disposed/sold 4,926 options to buy
@ $10.8, valued at
$53.2k
Disposed/sold 2,947 options to buy
@ $19.71, valued at
$58.1k
Disposed/sold 3,133 options to buy
@ $17, valued at
$53.3k
Disposed/sold 5,543 options to buy
@ $0 |
|
| 02/19/2021 |
4
| Belmont Terry (Director) has filed a Form 4 on Cellular Biomedicine Group, Inc.|
Txns:
| Disposed/sold 3,000 options to buy
@ $15.62, valued at
$46.9k
Disposed/sold 4,000 options to buy
@ $12.94, valued at
$51.8k
Disposed/sold 8,761 options to buy
@ $20, valued at
$175.2k
Disposed/sold 11,895 options to buy
@ $13.35, valued at
$158.8k
Disposed/sold 14,648 options to buy
@ $10.8, valued at
$158.2k
Disposed/sold 8,765 options to buy
@ $19.71, valued at
$172.8k
Disposed/sold 6,944 options to buy
@ $17, valued at
$118k
Disposed/sold 6,348 options to buy
@ $0 |
|
| 02/19/2021 |
4
| Zhou Hansheng (Director) has filed a Form 4 on Cellular Biomedicine Group, Inc.|
Txns:
| Disposed/sold 5,300 options to buy
@ $16, valued at
$84.8k
Disposed/sold 12,056 options to buy
@ $10.8, valued at
$130.2k
Disposed/sold 7,213 options to buy
@ $19.71, valued at
$142.2k
Disposed/sold 6,019 options to buy
@ $17, valued at
$102.3k
Disposed/sold 6,976 options to buy
@ $0 |
|
| 02/19/2021 |
4
| Schafer Edward T (Director) has filed a Form 4 on Cellular Biomedicine Group, Inc.|
Txns:
| Disposed/sold 5,044 options to buy
@ $14.93, valued at
$75.3k
Disposed/sold 4,983 options to buy
@ $0 |
|
| 02/19/2021 |
4
| Liu Wen Tao (Director) has filed a Form 4 on Cellular Biomedicine Group, Inc.|
Txns:
| Disposed/sold 213,076 shares
@ $0
Disposed/sold 146,667 options to buy
@ $3, valued at
$440k
Disposed/sold 5,477 options to buy
@ $17, valued at
$93.1k
Disposed/sold 6,348 options to buy
@ $0 |
|
| 02/19/2021 |
4
| Yao Yihong (Chief Scientific Officer) has filed a Form 4 on Cellular Biomedicine Group, Inc.|
Txns:
| Granted 54,000 shares
@ $0
Disposed of 88,549 shares
@ $0
Disposed/sold 18,900 shares
@ $0
Disposed of 25,000 options to buy
@ $26.53, valued at
$663.3k
Disposed of 10,000 options to buy
@ $18.61, valued at
$186.1k
Disposed of 26,500 options to buy
@ $12.4, valued at
$328.6k
|
|
| 02/19/2021 |
4
| Chan Andrew K (Ch Legal Ofr, Corp Dev & Sec) has filed a Form 4 on Cellular Biomedicine Group, Inc.|
Txns:
| Granted 48,000 shares
@ $0
Disposed/sold 239,747 shares
@ $0
Disposed/sold 38,880 options to buy
@ $3, valued at
$116.6k
Disposed/sold 37,904 options to buy
@ $5.61, valued at
$212.6k
Disposed of 15,000 options to buy
@ $18.61, valued at
$279.2k
Disposed/sold 15,000 options to buy
@ $12.55, valued at
$188.3k
Disposed/sold 23,000 options to buy
@ $12.4, valued at
$285.2k
|
|
| 02/19/2021 |
4
| Liu Tony (CEO, CFO) has filed a Form 4 on Cellular Biomedicine Group, Inc.|
Txns:
| Granted 240,000 shares
@ $0
Disposed of 476,817 shares
@ $0
Disposed/sold 10,700 shares
@ $0
Disposed of 5,300 options to buy
@ $7.23, valued at
$38.3k
Disposed of 255,000 options to buy
@ $5, valued at
$1.3M
Disposed of 15,000 options to buy
@ $20.63, valued at
$309.5k
Disposed of 105,800 options to buy
@ $15.53, valued at
$1.6M
Disposed of 30,000 options to buy
@ $35.53, valued at
$1.1M
Disposed of 40,000 options to buy
@ $20, valued at
$800k
Disposed of 30,000 options to buy
@ $12.55, valued at
$376.5k
Disposed of 120,000 options to buy
@ $12.4, valued at
$1.5M
|
|
| 02/19/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/19/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/19/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/19/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/19/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/19/2021 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers: [Amend] |
| 02/19/2021 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...|
Docs:
|
"AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CELLULAR BIOMEDICINE GROUP, INC. ARTICLE ONE The name of the corporation is Cellular Biomedicine Group, Inc. . ARTICLE TWO The address of the Corporation’s registered office is at Suite 302, 4001 Kennett Pike, County of New Castle, Wilmington, DE 19807. The name of its registered agent at such address is Maples Fiduciary Services Inc. ARTICLE THREE The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware . ARTICLE FOUR The total number of shares which the Corporation shall have the authority to issue is one thousand , all of which shall be shares of common stock, with a par value of one cent per share, and are to be of one ...",
"ARTICLES OF INCORPORATION / BYLAWS",
"CELLULAR BIOMEDICINE GROUP, INC. ANNOUNCES COMPLETION OF MERGER ROCKVILLE, MD and SHANGHAI, China – Cellular Biomedicine Group, Inc. today announced the completion of the merger of the Company with CBMG Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of CBMG Holdings, an exempted company with limited liability incorporated under the laws of the Cayman Islands , pursuant to the previously announced Agreement and Plan of Merger , dated as of August 11, 2020, by and among the Company, Parent and Merger Sub. Under the terms of the Merger Agreement, which was approved by the Company’s stockholders at its special meeting of stockholders held on February 8, 2021, each share of the Company’s common stock, par value $0.001 per share , issued and outstanding immediately prior ..." |
|
| 02/08/2021 |
8-K
| Quarterly results |
| 02/01/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/01/2021 |
8-K
| Quarterly results |
| 01/28/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/26/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/25/2021 |
GN
| SHAREHOLDER ALERT: Halper Sadeh LLP Investigates UROV, WTRE, CBMG, NAV; Shareholders Are Encouraged to Contact the Firm |
| 01/08/2021 |
GN
| MERGER INVESTIGATION: Halper Sadeh LLP Investigates CBMG, ALSK, UROV, NAV; Shareholders Are Encouraged to Contact the Firm |
| 12/29/2020 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers: [Amend] |
| 12/29/2020 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 12/28/2020 |
GN
| Rigrodsky & Long, P.A. Reminds Investors of Investigation of Cellular Biomedicine Group, Inc. Buyout |
| 12/12/2020 |
GN
| INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate the Following Companies; Shareholders are Encouraged to Contact the Firm – CBMG, MVC, STND, EIDX |
| 12/08/2020 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers: [Amend] |
|
|
|